268 related articles for article (PubMed ID: 33409484)
1. CART Cell Toxicities: New Insight into Mechanisms and Management.
Zahid A; Siegler EL; Kenderian SS
Clin Hematol Int; 2020 Dec; 2(4):149-155. PubMed ID: 33409484
[TBL] [Abstract][Full Text] [Related]
2. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
4. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
Siegler EL; Kenderian SS
Front Immunol; 2020; 11():1973. PubMed ID: 32983132
[TBL] [Abstract][Full Text] [Related]
6. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
[TBL] [Abstract][Full Text] [Related]
7. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment.
Rice J; Nagle S; Randall J; Hinson HE
Curr Treat Options Neurol; 2019 Jul; 21(8):40. PubMed ID: 31327064
[TBL] [Abstract][Full Text] [Related]
9. [The critically ill CAR T-cell patient : Relevant toxicities, their management and challenges in critical care].
Garcia Borrega J; Heindel K; Kochanek M; Warnke C; Stemmler J; von Bergwelt-Baildon M; Liebregts T; Böll B
Med Klin Intensivmed Notfmed; 2021 Mar; 116(2):121-128. PubMed ID: 33564900
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms and management of CAR T toxicity.
Ferreri CJ; Bhutani M
Front Oncol; 2024; 14():1396490. PubMed ID: 38835382
[TBL] [Abstract][Full Text] [Related]
11. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
12. In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.
Garcia Borrega J; Gödel P; Rüger MA; Onur ÖA; Shimabukuro-Vornhagen A; Kochanek M; Böll B
Hemasphere; 2019 Apr; 3(2):e191. PubMed ID: 31723828
[TBL] [Abstract][Full Text] [Related]
13. Toxicity of Chimeric Antigen Receptor T Cells and its Management.
Wudhikarn K; Soh SY; Huang H; Perales MA
Blood Cell Ther; 2021 Oct; 4(Spec Edition):S1-S7. PubMed ID: 36713468
[TBL] [Abstract][Full Text] [Related]
14. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
[TBL] [Abstract][Full Text] [Related]
15. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
Ong SY; Baird JH
J Intensive Care Med; 2023 Oct; ():8850666231205264. PubMed ID: 37899577
[TBL] [Abstract][Full Text] [Related]
16. Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy.
Gaffney KJ; Davis JA; McGann M; Edwards K; Ahmed Z; Butcher C; Greenwell B; Hess BT; Hashmi H
J Oncol Pharm Pract; 2024 Jan; 30(1):151-158. PubMed ID: 37097891
[TBL] [Abstract][Full Text] [Related]
17. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
18. Neurotoxicity Biology and Management.
Danish H; Santomasso BD
Cancer J; 2021 Mar-Apr 01; 27(2):126-133. PubMed ID: 33750072
[TBL] [Abstract][Full Text] [Related]
19. Novel pathophysiological insights into CAR-T cell associated neurotoxicity.
Genoud V; Migliorini D
Front Neurol; 2023; 14():1108297. PubMed ID: 36970518
[TBL] [Abstract][Full Text] [Related]
20. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.
Riegler LL; Jones GP; Lee DW
Ther Clin Risk Manag; 2019; 15():323-335. PubMed ID: 30880998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
